Introduction
Early in the COVID-19 pandemic, identifying biological markers to predict disease severity was a critical priority for clinical triage. While age and comorbidities were quickly established as risk factors, the role of host genetics—specifically the ABO blood group system—remained an area of active debate. This retrospective study aimed to describe the ABO blood group distribution and its association with the risk of severe COVID-19 infection to help identify susceptible populations and develop a simple predictive decision system.
Methods
Researchers conducted a retrospective clinical study at the Taizhou Hospital of Zhejiang Province, China, covering the period from January 21 to February 20, 2020. The study utilized a primary clinical dataset of 220 patients:
- Severe COVID-19: 32 patients
- Non-severe COVID-19: 106 patients
- Non-COVID-19 Control: 82 patients (suspected cases that tested negative via RT-PCR)
ABO blood groups were determined using an automated analyzer. The team also performed biochemical analyses, comparing laboratory indices such as liver enzymes (ALT) and tissue damage markers (LDH) between blood type O and non-O patients. Statistical modeling utilized Chi-square tests for categorical data and Odds Ratios (OR) with 95% confidence intervals to assess relative risk.
Results
Blood Group Distribution
The study found distinct trends in how blood groups were distributed across different clinical outcomes. While type O was prevalent in non-severe and control groups, its frequency was markedly lower in the severe category.
The "O" Advantage in Severe Cases
Statistical analysis confirmed that blood type O acts as a protective factor against severe disease progression. The data revealed a significant negative correlation between type O and severe infection, suggesting these individuals are less likely to require intensive clinical intervention.
Key statistical findings include:
- Risk Reduction: Patients with blood type O had a significantly lower risk of severe COVID-19 compared to other blood types (OR = 0.380, p = 0.044).
- Gender-Specific Resilience: The protective effect was particularly pronounced in females. In the female cohort, type O was strongly associated with lower severity (p = 0.049).
- Biochemical Validation: Type O patients exhibited significantly lower levels of Alanine Aminotransferase (ALT) and Lactate Dehydrogenase (LDH) compared to non-O patients. Since LDH is a marker for cell necrosis, its lower levels suggest less systemic damage to the liver and lungs in type O individuals.
Discussion and Conclusion
This study suggests that ABO blood groups may play a significant role in COVID-19 pathogenesis, with blood type O providing a degree of protection against severe clinical outcomes, especially in women. The authors hypothesize that this may be due to differences in humoral immune response profiles, as evidenced by lower CD19+ B cell ratios in type O patients.
Limitations
The authors acknowledge several constraints, including a relatively small sample size (n=220) and geographic homogeneity, as the cohort was limited to a single hospital in China. As an observational study, it identifies correlations but cannot definitively prove a causal mechanism. Future large-scale genomic studies are recommended to explore the direct interaction between blood group antigens and the SARS-CoV-2 virus.
Summary updated